A bill to require a report and updated guidance on continued risk management for pharmaceutical supply chains of Department of Defense.

Bill 118 s 4635, also known as the "Pharmaceutical Supply Chain Risk Management Act," is a proposed piece of legislation that aims to address the potential risks associated with the pharmaceutical supply chains of the Department of Defense (DoD). The bill calls for a report to be conducted on the current state of risk management within these supply chains, as well as updated guidance to ensure that any potential risks are effectively managed.

The bill recognizes the importance of ensuring the safety and reliability of pharmaceuticals within the DoD supply chain, particularly in light of recent events that have highlighted vulnerabilities in supply chains. By requiring a report on the current risk management practices and updated guidance to address any identified gaps, the bill seeks to enhance the overall security and resilience of the pharmaceutical supply chains within the Department of Defense.

Overall, Bill 118 s 4635 represents a proactive approach to addressing potential risks within the pharmaceutical supply chains of the Department of Defense, with the ultimate goal of ensuring the safety and effectiveness of pharmaceuticals for military personnel and their families.